

## Special Issue

# The Interaction of Cytomegalovirus with the Human Immune System

### Message from the Guest Editors

Cytomegalovirus (CMV) infection is typically asymptomatic or mild in immunologically normal hosts. The mechanisms of virus-immune interactions that culminate in the wide range of observed clinical outcomes in these groups are insufficiently understood.

Advances in prevention and treatment strategies depend on more detailed knowledge of these mechanisms, their relative significance, and their local tissue context, particularly those leading to more severe disease or viral transmission from transplanted organ to recipient or from mother to fetus. This new knowledge can then be applied to the design of immune-based interventions that maximize protection while reducing the risk of pathologic effects. In support of such progress, this special issue of *Vaccines* curates a series of impactful studies that delve into essential elements of the interaction between CMV and the human immune system. We invite you to join in sharing knowledge so that our collective wisdom continues to advance the CMV field into the future.

---

### Guest Editors

Dr. Laura L. Gibson

Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA

Prof. Dr. Matthew Reeves

Institute for Immunity and Transplantation, London's Global University, London NW3 2PF, UK

---

### Deadline for manuscript submissions

closed (31 December 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/93649](https://mdpi.com/si/93649)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).